Doctors working with Paige technology
Source: Paige
Microsoft announced Thursday it’s teaming up with digital pathology provider Paige to construct the world’s largest image-based artificial intelligence model for identifying cancer.
The AI model is training on an unprecedented amount of knowledge that features billions of images, in response to a release. It will possibly discover each common cancers and rare cancers which are notoriously difficult to diagnose, and researchers hope it can eventually help doctors who’re struggling to contend with staffing shortages and growing caseloads.
Paige develops digital and AI-powered solutions for pathologists, that are doctors who perform lab tests on bodily fluids and tissues to make a diagnosis. It is a specialty that usually operates behind the scenes, and it’s crucial for determining a patient’s path forward.
“You haven’t got cancer until the pathologist says so. That is the critical step in the entire medical edifice,” Thomas Fuchs, co-founder and chief scientist at Paige, told CNBC in an interview.
But despite pathologists’ essential role in medicine, Fuchs said their workflow has not modified much within the last 150 years. To diagnose cancer, for example, pathologists normally examine a chunk of tissue on a glass slide under a microscope. The strategy is tried and true, but when pathologists miss something, it could actually have dire consequences for patients.
Consequently, Paige has been working to digitize the pathologists’ workflow to enhance accuracy and efficiency inside the specialty.
Doctors working with Paige technology
Source: Paige
The corporate has received approval from the Food and Drug Administration for its viewing tool FullFocus, which allows pathologists to look at scanned digital slides on a screen as a substitute of counting on a microscope. Paige also built an AI model that might help pathologists discover breast cancer, colon cancer and prostate cancer when it appears on the screen.
Digital pathology is expensive
Paige is the one company that has received FDA approval for pathologists to make use of its AI as a secondary tool for identifying prostate cancer, and CEO Andy Moye said this is probably going partly due to barriers related to storage costs and data collection.
Digitizing a single slide can require over a gigabyte of storage, so the infrastructure and costs related to large-scale data collection balloon quickly. Fuchs said the storage costs may be inhibiting for smaller health systems, which is why wealthy academic centers have historically been the one organizations that may afford to speculate in digital pathology.
Paige spun out of the Memorial Sloan Kettering Cancer Center in Latest York in 2017 and has a “improbable wealth of knowledge,” in response to Moye, which is why the corporate was in a position to construct its own AI-powered solutions in the primary place. To place the size in perspective, Paige has 10 times more data than Netflix, including all of the shows and flicks that exist on the platform.
But with the intention to expand its operations and construct an AI tool that may discover more cancer types, Paige turned to Microsoft for help. Over the past 12 months and a half, Paige has been using Microsoft’s cloud storage and supercomputing infrastructure to construct a sophisticated latest AI model.
Paige’s original AI model used greater than 1 billion images from 500,000 pathology slides, but Fuchs said the model the corporate has built with Microsoft is “orders of magnitude larger than anything on the market.” The model is training on 4 million slides to discover each common and rare cancers, which may be difficult to diagnose. Paige said it’s the biggest computer vision model that has ever been announced publicly.
“Until ChatGPT got released, nobody really understood how that is going to affect their lives. I might argue this could be very similar for cancer patients going forward,” Moye said. “That is kind of a groundbreaking, land-on-the-moon form of moment for cancer care.”
Moye added that the corporate is pondering of the way to include predictive modeling to offer pathologists and patients quick access to details about their biomarkers and genomic mutations down the road.
Desney Tan, vice chairman and managing director of Microsoft Health Futures, said Microsoft’s infrastructure is a key component of the partnership, but that the corporate can also be working to develop the brand new algorithms, detection and diagnostics that Paige is hoping to deliver in the subsequent couple of years.
He added that though the technology is powerful, it’s meant to complement pathologists, not replace them.
“We predict of those AI implements, these technologies, as tools, really just because the stethoscope is a tool, just because the X-ray machine is a tool,” Tan told CNBC in an interview. “AI is a tool that’s to be wielded by a human.”
On Thursday, Paige and Microsoft will publish a paper on the model through Cornell University’s preprint server arXiv. The paper quantifies the impact of the brand new model compared with existing models, and Fuchs said it outperforms anything that has been inbuilt academia up thus far.
However the preprint is just step one of a for much longer journey. Paige desired to make the research available to the broader community while it’s under peer review, and the corporate intends to undergo the scientific journal Nature. The method can take months, if not longer. Paige also has years of labor ahead before it can have the option to roll the model out as a product — including thorough testing and collaboration with regulators to make sure it’s protected and accurate.
Ultimately, Fuchs said the AI model will solve the storage problem for health systems, while also helping pathologists work through cases and arrive at a diagnosis more quickly. For some patients, it could mean the difference between waiting two days and two weeks to search out out what’s incorrect.
“The more you go away from academic medical centers, especially in community clinics where pathologists are completely overwhelmed across all cancer types with so many cases, there, the impact is kind of drastic,” Fuchs said. “That basically helps to democratize access to health care in these places.”